Identification of a Serum Biomarker Signature Associated with Metastatic Prostate Cancer

Overview

Journal Proteomics Clin Appl

Specialty Biochemistry

Date 2021 Feb 13

PMID 33580906

Citations 4

Authors

Venera Kuci Emruli

Leena Liljedahl

Ulrika Axelsson

Corinna Richter

Lisa Theorin

Anders Bjartell

Hans Lilja

Jenny Donovan

David Neal

Freddie C Hamdy

Carl A K Borrebaeck

Affiliations

Soon will be listed here.

Abstract

Purpose: Improved early diagnosis and determination of aggressiveness of prostate cancer (PC) is important to select suitable treatment options and to decrease over-treatment. The conventional marker is total prostate specific antigen (PSA) levels in blood, but lacks specificity and ability to accurately discriminate indolent from aggressive disease.

Experimental Design: In this study, we sought to identify a serum biomarker signature associated with metastatic PC. We measured 157 analytes in 363 serum samples from healthy subjects, patients with non-metastatic PC and patients with metastatic PC, using a recombinant antibody microarray.

Results: A signature consisting of 69 proteins differentiating metastatic PC patients from healthy controls was identified.

Conclusions And Clinical Relevance: The clinical value of this biomarker signature requires validation in larger independent patient cohorts before providing a new prospect for detection of metastatic PC.

Citing Articles

AAT resistance-related AC007405.2 and AL354989.1 as novel diagnostic and prognostic markers in prostate cancer.

Deng Y, Zhang C, Yu H, Chen G, Peng X, Li Y Aging (Albany NY). 2024; 16(8):7249-7266.

PMID: 38643469 PMC: 11087092. DOI: 10.18632/aging.205754.

Laser-assisted protein micropatterning in a thermoplastic device for multiplexed prostate cancer biomarker detection.

Kling A, Dirscherl L, Dittrich P Lab Chip. 2023; 23(3):534-541.

PMID: 36642981 PMC: 9890490. DOI: 10.1039/d2lc00840h.

Urine Exosomal AMACR Is a Novel Biomarker for Prostate Cancer Detection at Initial Biopsy.

Jin X, Ji J, Niu D, Yang Y, Tao S, Wan L Front Oncol. 2022; 12:904315.

PMID: 35795046 PMC: 9251007. DOI: 10.3389/fonc.2022.904315.

A Novel Urine Exosomal lncRNA Assay to Improve the Detection of Prostate Cancer at Initial Biopsy: A Retrospective Multicenter Diagnostic Feasibility Study.

Li Y, Ji J, Lyu J, Jin X, He X, Mo S Cancers (Basel). 2021; 13(16).

PMID: 34439239 PMC: 8393262. DOI: 10.3390/cancers13164075.

References

Carlsson A, Wingren C, Ingvarsson J, Ellmark P, Baldertorp B, Ferno M . Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays. Eur J Cancer. 2008; 44(3):472-80. DOI: 10.1016/j.ejca.2007.11.025. View

Kharmate G, Hosseini-Beheshti E, Caradec J, Chin M, Guns E . Epidermal Growth Factor Receptor in Prostate Cancer Derived Exosomes. PLoS One. 2016; 11(5):e0154967. PMC: 4859494. DOI: 10.1371/journal.pone.0154967. View

Day K, Hiles G, Kozminsky M, Dawsey S, Paul A, Broses L . HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. Cancer Res. 2016; 77(1):74-85. PMC: 5214538. DOI: 10.1158/0008-5472.CAN-16-1656. View

Borrebaeck C, Wingren C . Recombinant antibodies for the generation of antibody arrays. Methods Mol Biol. 2011; 785:247-62. DOI: 10.1007/978-1-61779-286-1_17. View

Wingren C, Ingvarsson J, Dexlin L, Szul D, Borrebaeck C . Design of recombinant antibody microarrays for complex proteome analysis: choice of sample labeling-tag and solid support. Proteomics. 2007; 7(17):3055-65. DOI: 10.1002/pmic.200700025. View

Lehrer S, Diamond E, Mamkine B, Stone N, Stock R . Serum interleukin-8 is elevated in men with prostate cancer and bone metastases. Technol Cancer Res Treat. 2004; 3(5):411. DOI: 10.1177/153303460400300501. View

Vaday G, Peehl D, Kadam P, Lawrence D . Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate. 2005; 66(2):124-34. DOI: 10.1002/pros.20306. View

Maynard J, Ertunc O, Kulac I, Baena-Del Valle J, De Marzo A, Sfanos K . IL8 Expression Is Associated with Prostate Cancer Aggressiveness and Androgen Receptor Loss in Primary and Metastatic Prostate Cancer. Mol Cancer Res. 2019; 18(1):153-165. DOI: 10.1158/1541-7786.MCR-19-0595. View

Catalona W, Partin A, Slawin K, Brawer M, Flanigan R, Patel A . Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998; 279(19):1542-7. DOI: 10.1001/jama.279.19.1542. View

10.

Johnson W, Li C, Rabinovic A . Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2006; 8(1):118-27. DOI: 10.1093/biostatistics/kxj037. View

11.

Gronberg H, Adolfsson J, Aly M, Nordstrom T, Wiklund P, Brandberg Y . Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol. 2015; 16(16):1667-76. DOI: 10.1016/S1470-2045(15)00361-7. View

12.

Gerdtsson A, Wingren C, Persson H, Delfani P, Nordstrom M, Ren H . Plasma protein profiling in a stage defined pancreatic cancer cohort - Implications for early diagnosis. Mol Oncol. 2016; 10(8):1305-16. PMC: 5423191. DOI: 10.1016/j.molonc.2016.07.001. View

13.

Sall A, Walle M, Wingren C, Muller S, Nyman T, Vala A . Generation and analyses of human synthetic antibody libraries and their application for protein microarrays. Protein Eng Des Sel. 2016; 29(10):427-437. DOI: 10.1093/protein/gzw042. View

14.

Ahmed H, El-Shater Bosaily A, Brown L, Gabe R, Kaplan R, Parmar M . Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017; 389(10071):815-822. DOI: 10.1016/S0140-6736(16)32401-1. View

15.

Pauly F, Dexlin-Mellby L, Ek S, Ohlin M, Olsson N, Jirstrom K . Protein expression profiling of formalin-fixed paraffin-embedded tissue using recombinant antibody microarrays. J Proteome Res. 2013; 12(12):5943-53. DOI: 10.1021/pr4003245. View

16.

Carlsson A, Wingren C, Kristensson M, Rose C, Ferno M, Olsson H . Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases. Proc Natl Acad Sci U S A. 2011; 108(34):14252-7. PMC: 3161545. DOI: 10.1073/pnas.1103125108. View

17.

Smith C, Laucis A, Harmon S, Mena E, Lindenberg L, Choyke P . Novel Imaging in Detection of Metastatic Prostate Cancer. Curr Oncol Rep. 2019; 21(4):31. DOI: 10.1007/s11912-019-0780-8. View

18.

Kolde R, Laur S, Adler P, Vilo J . Robust rank aggregation for gene list integration and meta-analysis. Bioinformatics. 2012; 28(4):573-80. PMC: 3278763. DOI: 10.1093/bioinformatics/btr709. View

19.

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View

20.

Bryant R, Yang B, Philippou Y, Lam K, Obiakor M, Ayers J . Does the introduction of prostate multiparametric magnetic resonance imaging into the active surveillance protocol for localized prostate cancer improve patient re-classification?. BJU Int. 2018; 122(5):794-800. DOI: 10.1111/bju.14248. View